[{"id":"80ae9b9a-9383-4fbe-a030-18f6cfe6115b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03798626","created_at":"2021-01-18T18:47:09.510Z","updated_at":"2024-07-02T16:35:03.688Z","phase":"Phase 1","brief_title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","source_id_and_acronym":"NCT03798626","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 167","initiation":"Initiation: 05/22/2019","start_date":" 05/22/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-14"}]